Quiviviq (Daridorexant) - Dosing, Contraindications, and Precautions
The recommended dosage of Quiviviq is 25-50 mg taken orally once nightly within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening. 1
Standard Dosing
- Initial and maintenance dose: 25-50 mg once per night
- Timing: Within 30 minutes before going to bed
- Minimum sleep opportunity: At least 7 hours remaining prior to planned awakening
- Food interaction: Time to sleep onset may be delayed if taken with or soon after a meal 1
Dose Adjustments
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh score 7-9): Maximum dose 25 mg once nightly 1
- Severe hepatic impairment (Child-Pugh score ≥10): Not recommended 1
Drug Interactions Requiring Dose Modification
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Avoid concomitant use 1
- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin): Maximum dose 25 mg once nightly 1
- Strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): Avoid concomitant use 1
Special Populations
- Renal impairment: No dose adjustment needed for mild-to-moderate kidney impairment 2
- Elderly patients: No specific dose adjustment required; same dosing as younger adults 2, 3
- Sex, race, body size: No dose adjustments needed 2
Absolute Contraindications
Quiviviq is contraindicated in two specific situations:
- Narcolepsy 1
- Known hypersensitivity to daridorexant or any components - Angioedema with pharyngeal involvement has been reported 1
Critical Warnings and Precautions
CNS Depression and Next-Day Impairment
This is the most clinically significant concern. Daridorexant impairs daytime wakefulness and driving ability even when used as prescribed. 1
Driving impairment: Documented in subjects taking 50 mg dose 1
Duration of effects: CNS-depressant effects may persist for several days after discontinuation 1
Risk factors for increased impairment:
- Taking with less than 7 hours of sleep remaining
- Taking higher than recommended dose
- Concomitant use with other CNS depressants (benzodiazepines, opioids, tricyclic antidepressants)
- Alcohol co-administration: Additive psychomotor impairment - advise patients to avoid alcohol completely 1
Fall risk: Elderly patients are at higher risk due to drowsiness 1
Psychiatric Effects
- Worsening depression/suicidal ideation: Monitor patients with psychiatric disorders, particularly depression 1
- Sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms: May occur with use 1
Complex Sleep Behaviors
Discontinue immediately if these occur:
- Sleepwalking
- Sleep driving
- Engaging in other activities while not fully awake 1
Compromised Respiratory Function
Consider the effect on respiratory function, particularly in patients with underlying respiratory conditions 1
Persistent Insomnia
Reevaluate if insomnia persists after 7-10 days of treatment - this may indicate an underlying psychiatric or medical condition requiring alternative management 1
Common Adverse Events
The most frequently reported adverse reactions (≥5% and greater than placebo):
- Headache
- Somnolence or fatigue 1
Additional adverse events from clinical trials:
- Nasopharyngitis
- Gait disturbance
- Diarrhea 3
Meta-analysis data shows daridorexant has a slightly higher incidence of adverse events compared to placebo, specifically somnolence and fatigue 4
Clinical Efficacy Context
Daridorexant demonstrates significant improvements in both objective and subjective sleep parameters:
- Wake after sleep onset (WASO): Reduced by 18-29 minutes at months 1 and 3 5
- Latency to persistent sleep (LPS): Reduced by 28-35 minutes 5
- Total sleep time: Increased by approximately 15 minutes 4
The 25 mg dose maintains efficacy over 3 months, particularly for objective sleep metrics 6. Efficacy is sustained for up to 1 year with favorable tolerability 7.